Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Medtronic
Novartis
McKesson
Fuji
Citi
Chinese Patent Office
Harvard Business School
Cerilliant
Merck

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,017,615

« Back to Dashboard

Which drugs does patent 8,017,615 protect, and when does it expire?

Patent 8,017,615 protects ABILIFY and is included in two NDAs.

Protection for ABILIFY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and forty-eight patent family members in thirty-one countries.
Summary for Patent: 8,017,615
Title:Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period.
Inventor(s): Bando; Takuji (Tokushima, JP), Aoki; Satoshi (Naruto, JP), Kawasaki; Junichi (Tokushima, JP), Ishigami; Makoto (Tokushima, JP), Taniguchi; Youichi (Tokushima, JP), Yabuuchi; Tsuyoshi (Tokushima, JP), Fujimoto; Kiyoshi (Naruto, JP), Nishioka; Yoshihiro (Tokushima, JP), Kobayashi; Noriyuki (Tokushima, JP), Fujimura; Tsutomu (Naruto, JP), Takahashi; Masanori (Tokushima, JP), Abe; Kaoru (Tokushima, JP), Nakagawa; Tomonori (Tokushima, JP), Shinhama; Koichi (Tokushima, JP), Utsumi; Naoto (Naruto, JP), Tominaga; Michiaki (Tokushima, JP), Ooi; Yoshihiro (Tokushima, JP), Yamada; Shohei (Tokushima, JP), Tomikawa; Kenji (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:11/790,605
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Process;

Drugs Protected by US Patent 8,017,615

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Otsuka ABILIFY aripiprazole TABLET, ORALLY DISINTEGRATING;ORAL 021729-002 Jun 7, 2006 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Otsuka ABILIFY aripiprazole TABLET, ORALLY DISINTEGRATING;ORAL 021729-003 Jun 7, 2006 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Otsuka ABILIFY aripiprazole TABLET, ORALLY DISINTEGRATING;ORAL 021729-004 Jun 7, 2006 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Otsuka ABILIFY aripiprazole TABLET, ORALLY DISINTEGRATING;ORAL 021729-005 Jun 7, 2006 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Otsuka ABILIFY aripiprazole TABLET;ORAL 021436-006 Nov 15, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Otsuka ABILIFY aripiprazole TABLET;ORAL 021436-005 Nov 15, 2002 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Otsuka ABILIFY aripiprazole TABLET;ORAL 021436-001 Nov 15, 2002 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Otsuka ABILIFY aripiprazole TABLET;ORAL 021436-002 Nov 15, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Otsuka ABILIFY aripiprazole TABLET;ORAL 021436-003 Nov 15, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Otsuka ABILIFY aripiprazole TABLET;ORAL 021436-004 Nov 15, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,017,615

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2001-290645Sep 25, 2001
Japan2001-348276Nov 14, 2001
Canada2379005Mar 27, 2002

Non-Orange Book US Patents Family Members for Patent 8,017,615

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,703,772 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Subscribe
7,910,589 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Subscribe
8,901,303 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Subscribe
8,399,469 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Subscribe
8,703,773 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Subscribe
8,642,760 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Subscribe
8,580,796 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Subscribe
9,359,302 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Subscribe
8,901,130 Low hygroscopic aripiprazole drug substance and processes for the preparation ➤ Subscribe
8,993,761 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,017,615

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 033485 ➤ Subscribe
Argentina 056503 ➤ Subscribe
Argentina 073111 ➤ Subscribe
Argentina 077635 ➤ Subscribe
Argentina 087544 ➤ Subscribe
Austria 322269 ➤ Subscribe
Austria 464050 ➤ Subscribe
Austria 465736 ➤ Subscribe
Austria 465737 ➤ Subscribe
Austria 467416 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Novartis
Citi
Deloitte
Johnson and Johnson
Covington
Daiichi Sankyo
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot